Treatment-Resistant Depression Market Size in the 7MM was ~USD 3,100 million in 2022 and it is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Treatment Resistant Depression Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of historical and forecasted epidemiology as well as Treatment-Resistant Depression therapeutics market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Treatment Resistant Depression Market Share @ Treatment Resistant Depression Market Outlook- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Treatment Resistant Depression Market Report
• On April 17, 2026- Navitor Pharmaceuticals Inc. announced a phase 2 study will evaluate the efficacy and safety of NV-5138 in adults with TRD.
• On April 17, 2026- ACADIA Pharmaceuticals Inc. initiated a clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).
• The total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM were approximately 6,409,000 cases in 2022 and are projected to increase during the forecast period (2023-2032).
• The United States contributed to the largest number of diagnosed prevalent cases of Treatment-Resistant Depression (~71%) in the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 25% and 4% of the total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM, respectively, in 2022.
• Among the EU4 countries, Germany accounted for the highest number of total diagnosed prevalent cases of Treatment-Resistant Depression, whereas Italy accounted for the lowest number of cases in 2022.
• DelveInsight estimates that around 512,000 cases and 1,117,000 cases of Treatment-Resistant Depression were observed in males and females, respectively, in EU4 and the UK in 2022. The cases are projected to increase during the forecast period.
• In 2022, the maximum number of cases of Treatment-Resistant Depression was found in 50-60 years, and the least number of cases were found in 18-29 years in the US.
• The leading Treatment Resistant Depression Companies such as Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
• Promising Treatment Resistant Depression Pipeline Therapies such as NV5138, MIJ821, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others.

Stay ahead in the Treatment Resistant Depression Therapeutics Market with DelveInsight's Strategic Report @ Treatment Resistant Depression Market Outlook- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment Resistant Depression Epidemiology Segmentation in the 7MM
• Total Treatment Resistant Depression Prevalent Cases
• Treatment Resistant Depression Age-specific Cases
• Treatment Resistant Depression Gender-specific Cases
• Treatment Resistant Depression Treated Cases

Download the report to understand which factors are driving Treatment Resistant Depression Epidemiology Trends @ Treatment Resistant Depression Prevalence- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment-Resistant Depression Marketed Drugs
• SPRAVATO (esketamine): Johnson & Johnson
SPRAVATO (esketamine) is the only nasal spray treatment indicated for Treatment-Resistant Depression. It is an NMDA receptor antagonist believed to work differently by acting on a pathway in the brain that affects glutamate. It has the first new mechanism of action in decades to treat Major Depressive Disorder. In March 2019, the FDA approved SPRAVATO as an oral antidepressant in adults with Treatment-Resistant Depression. But since then, the drug has faced many challenges as the insurance companies tried to understand the treatment and how it worked. SPRAVATO is given through Risk Evaluation and Mitigation Strategy (REMS) program. The drug also comes with a black box warning highlighting sedation; dissociation; abuse and misuse; and suicidal thoughts and behaviors. With limited treatment options, this drug was a ray of hope for all Treatment-Resistant Depression patients, but it seems that the drug has not generated enough revenue to be called a blockbuster. Currently, Johnson & Johnson is not reporting any revenue from this product. As per their latest reports, the product should have crossed the threshold revenue so that it could be reported separately, but it seems the drug has still not achieved it.

Treatment-Resistant Depression Emerging Drugs
• MIJ821: Novartis
MIJ821 is a potent, subtype-selective NMDAr 2B receptor, the negative allosteric modulator (NAM). The product was discovered by Cadent Therapeutics to produce rapid ketamine relief to patients without ketamine like side-effects. Later, Cadent Therapeutics licensed the intellectual property for NMDA receptor compounds (MIJ821) that selectively modulate NR2B to Novartis exclusively. The drug is undergoing a Phase II proof of concept study, the detailed results of which are still awaited.

• COMP360 (Psilocybin): COMPASS Pathways
COMP360 (Psilocybin) are naturally occurring magic mushrooms consumed for their hallucinogenic effects. It has a high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous brain areas, including the cerebral cortex and thalamus. They belong to a group of drugs known as psychedelics because of the changes experienced in perception, mood, and thought.

Treatment-Resistant Depression Drugs Market Insights
The current treatment of Treatment-Resistant Depression consists of different approaches classified into pharmacologic and nonpharmacological therapies. Pharmacologic treatment options include switching, combination, and potentiation strategizing among the commonly used antidepressant drugs. Most of the available antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, non-selective monoamine oxidase inhibitors (MAOIs), a2-antagonists, agomelatine, and tianeptine are used to treat Treatment-Resistant Depression.

To learn more about Treatment Resistant Depression treatment guidelines, visit @ Treatment Resistant Depression Treatment Market Landscape- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment-Resistant Depression Market Outlook
Treatment-Resistant Depression is usually linked to higher rates of comorbidity, particularly with other psychiatric disorders, chronic pain, and fibromyalgia. On the other hand, the impact of physical and psychiatric illness comorbidities is much higher among Treatment-Resistant Depression patients. Some environmental factors related to Treatment-Resistant Depression are lower socioeconomic status, non-supportive social environment, family conflicts, chronic stressors, multiple loss events, lower level of education, and social support and work dysfunction.

Treatment-Resistant Depression Treatment
Treatment options include switching, combination, and potentiation strategy among the commonly used antidepressant drugs. Most of the available antidepressants, such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressants, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), a2-antagonists, Agomelatine, Tianeptine are used to treat Treatment-Resistant Depression. SPRAVATO and SYMBYAX are the two FDA-approved drugs specifically for the treatment of Treatment-Resistant Depression. Other pharmacologic alternatives are also considered those having an antidepressant action such as in monotherapy: Bupropion, selective and reversible MAOIs, Quetiapine, and in combination with a first-line antidepressant: lithium, Lamotrigine, and second-generation antipsychotics. Nonpharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).

Learn more about the FDA-approved drugs for Treatment Resistant Depression @ Drugs for Treatment Resistant Depression Treatment- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Treatment Resistant Depression Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Treatment Resistant Depression Companies- Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and several others.
• Treatment Resistant Depression Pipeline Therapies- NV5138, MIJ821, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others.
• Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression Market Drivers and Barriers

Discover more about Treatment Resistant Depression Drugs in development @ Treatment Resistant Depression Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Report Introduction
2. Treatment Resistant Depression Market Overview at a Glance
3. Executive Summary of Treatment-Resistant Depression (TRD)
4. Key Events
5. Treatment Resistant Depression Disease Background and Overview
6. Treatment Resistant Depression Treatment
7. Treatment Resistant Depression Methodology
8. Treatment Resistant Depression Epidemiology and Patient Population
9. Patient Journey
10. Treatment Resistant Depression Marketed Drugs
11. Treatment Resistant Depression Emerging Drugs
12. Treatment-Resistant Depression (TRD): Seven Major Market Analysis
13. Treatment Resistant Depression KOL Views
14. Treatment Resistant Depression SWOT Analysis
15. Treatment Resistant Depression Unmet Needs
16. Reimbursement and Market Access
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.